WAVE LIFE SCIENCES LTD. Increase (Decrease) in Accounts Receivable
WAVE LIFE SCIENCES LTD. (WVE) reported Increase (Decrease) in Accounts Receivable of -$388.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-07-30
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $888.00K, a 45.08% decline year-over-year.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$1.28M.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$8.72M, a 713.50% decline year-over-year.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $8.38M.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts receivable for fiscal 2025 was -$146.00K.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts receivable for fiscal 2024 was -$19.66M, a 193.26% decline from fiscal 2023.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts receivable for fiscal 2023 was $21.09M.
- WAVE LIFE SCIENCES LTD. increase (decrease) in accounts receivable for fiscal 2021 was -$30.00M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 6 month as first filed | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $888.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$388.00K 10-Q · filed 2026-07-30 | -$9.11M derived: sum of 3 quarters · filed 2026-07-30 | -$729.00K derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | -$1.28M 10-Q · filed 2026-04-28 | -$10.00M derived: sum of 2 quarters · filed 2026-04-28 | -$1.62M derived: sum of 3 quarters · filed 2026-04-28 | $0.00 derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | -$8.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$341.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.28M derived: sum of 3 quarters · filed 2026-07-30 | -$146.00K 10-K · filed 2026-02-26 | |
| 2025-09-30 | $8.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $10.00M derived: sum of 2 quarters · filed 2026-07-30 | $8.58M 10-Q · filed 2025-11-10 | $10.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $195.00K 10-Q · filed 2026-07-30 | $1.62M derived: sum of 3 quarters · filed 2026-07-30 | $327.00K derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | -$1.42M 10-Q · filed 2026-04-28 | $0.00 derived: sum of 2 quarters · filed 2026-04-28 | -$1.29M derived: sum of 3 quarters · filed 2026-04-28 | $0.00 derived: sum of 4 quarters · filed 2026-04-28 | |
| 2024-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $132.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.42M derived: sum of 3 quarters · filed 2026-02-26 | -$19.66M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$1.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | -$21.09M 10-Q · filed 2025-11-10 | -$7.00M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | -$19.80M 10-Q · filed 2025-07-30 | -$5.71M derived: sum of 3 quarters · filed 2026-02-26 | $1.29M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | -$21.09M 10-Q · filed 2025-05-08 | -$7.00M derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $14.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.09M derived: sum of 2 quarters · filed 2026-02-26 | $21.09M derived: sum of 3 quarters · filed 2026-02-26 | $21.09M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $7.00M derived: sum of 2 quarters · filed 2024-11-12 | $7.00M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | ||||
| 2021-12-31 | -$22.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$60.00M derived: sum of 2 quarters · filed 2023-03-23 | -$30.00M 10-K · filed 2023-03-23 | ||
| 2021-09-30 | -$37.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$7.50M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $30.00M 10-Q · filed 2022-08-11 | -$30.00M 10-Q · filed 2021-08-05 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $0.00 derived: sum of 2 quarters · filed 2022-03-03 | $0.00 derived: sum of 3 quarters · filed 2022-03-03 | -$20.00M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | -$20.00M 10-Q · filed 2021-11-10 | -$20.00M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$20.00M 10-Q · filed 2021-08-05 | -$20.00M derived: sum of 3 quarters · filed 2021-08-05 | -$20.00M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$20.00M 10-Q · filed 2021-05-13 | -$20.00M derived: sum of 2 quarters · filed 2021-05-13 | -$20.00M derived: sum of 3 quarters · filed 2021-05-13 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $0.00 derived: sum of 2 quarters · filed 2021-03-04 | -$10.00M 10-K · filed 2021-03-04 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$10.00M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | -$10.00M 10-Q · filed 2020-08-10 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$5.00M derived: sum of 2 quarters · filed 2020-03-02 | $60.00M derived: sum of 3 quarters · filed 2020-03-02 | $59.00M 10-K · filed 2020-03-02 | |
| 2018-09-30 | -$5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $60.00M derived: sum of 2 quarters · filed 2019-11-05 | $59.00M 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $65.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $64.00M 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | -$1.00M 10-Q · filed 2019-05-10 | ||||
| 2017-12-31 | $1.00M 10-K · filed 2020-03-02 | ||||
| 2016-09-30 | $2.50M 10-Q · filed 2017-11-09 | ||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $7.00K derived: sum of 2 quarters · filed 2017-03-16 | -$224.00K derived: sum of 3 quarters · filed 2017-03-16 | -$193.00K 10-K · filed 2017-03-16 | |
| 2015-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$224.00K derived: sum of 2 quarters · filed 2016-11-09 | -$193.00K 10-Q · filed 2016-11-09 | $4.00K derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-06-30 | -$231.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$200.00K 10-Q · filed 2016-08-15 | -$3.00K derived: sum of 3 quarters · filed 2017-03-16 | ||
| 2015-03-31 | $31.00K 10-Q · filed 2016-05-16 | $228.00K derived: sum of 2 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $197.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $129.00K 10-K · filed 2017-03-16 | |||
| 2014-09-30 | -$68.00K 10-Q · filed 2015-12-17 | ||||
| 2013-12-31 | $102.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |